AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
March 07, 2022 08:50 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in...
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 29, 2021 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
November 15, 2021 19:24 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
November 15, 2021 09:00 ET
|
AnaptysBio, Inc.
Rosnilimab, AnaptysBio’s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohortsRobust pharmacokinetic...
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
November 04, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meetingTop-line data from ongoing imsidolimab ACORN...
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
October 25, 2021 16:37 ET
|
AnaptysBio, Inc.
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty PartnersSagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below...
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
October 02, 2021 12:00 ET
|
AnaptysBio, Inc.
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema...
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
August 17, 2021 16:32 ET
|
AnaptysBio, Inc.
Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April...